Emamectin benzoate-induced toxicity affects intestinal epithelial integrity involving apoptosis

The frequency presence of emamectin benzoate in agricultural production highlights the need for studying their toxicity against human intestinal epithelial barrier (IEB). Herein, we combined a Caco-2 cell model with transcriptome analysis to assess the intestinal toxicity of emamectin benzoate and i...

Full description

Saved in:
Bibliographic Details
Published inFood and chemical toxicology Vol. 190; p. 114827
Main Authors Yue, Xingyu, Lin, Fengxiang, Gui, Shuyan, Zhang, Sai, Wu, Zongbin, Xiang, Yuxin, Xiao, Tianxiang, Xiao, Jinjing, Cao, Haiqun, Shi, Yanhong
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.08.2024
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The frequency presence of emamectin benzoate in agricultural production highlights the need for studying their toxicity against human intestinal epithelial barrier (IEB). Herein, we combined a Caco-2 cell model with transcriptome analysis to assess the intestinal toxicity of emamectin benzoate and its disease-causing potential. Results showed that the half maximal inhibitory concentration (IC50) of emamectin benzoate on Caco-2 cell viability after 24, 48, and 72 h of exposure were 18.1, 9.9, and 8.3 μM, respectively. Emamectin benzoate exposure enhanced the Caco-2 monolayer paracellular permeability, damaged the IEB, and increased cellular apoptosis. Key driver gene analysis of 42 apoptosis - related DEGs, identified 10 genes (XIAP, KRAS, MCL1, NRAS, PIK3CA, CYCS, MAPK8, CASP3, FADD, and TNFRSF10B) with the strongest correlation with emamectin benzoate - induced apoptosis. Transcriptomics identified 326 differentially expressed genes (DEGs, 204 upregulated and 122 downregulated). The functional terms of neurodegeneration - multiple diseases was enriched with the most number of DEGs, and the Parkinson disease pathway had the highest enrichment degree. Our findings provided support for environmental toxicology studies and the health risk assessment of emamectin benzoate. [Display omitted]
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0278-6915
1873-6351
1873-6351
DOI:10.1016/j.fct.2024.114827